GLOW 70 Blend in Australia: BPC-157, GHK-Cu & TB-500 Research Guide

GLOW 70 is a pre-formulated three-compound lyophilised research vial containing BPC-157, GHK-Cu (copper peptide), and TB-500. The vial contains 70mg total, GHK-Cu at 50mg, with BPC-157 and TB-500 at 10mg each. This weighting reflects GHK-Cu's role as the primary collagen-remodelling and regenerative compound in the blend.

The formulation is designed for researchers studying multi-pathway tissue repair and inflammation biology who want to administer all three compounds from a single reconstituted preparation, without the need to source and reconstitute each peptide separately.

BPC-157 is a synthetic 15-amino acid peptide derived from a naturally occurring protein in human gastric juice. It is among the most studied research peptides, with preclinical data covering tendon and ligament repair, angiogenesis, gastrointestinal healing, and neuroprotection.

Key mechanisms include VEGF upregulation (promoting new blood vessel formation), upregulation of growth hormone receptor expression in tendon fibroblasts, and modulation of the nitric oxide system. In the GLOW 70 context, BPC-157 contributes localised tissue repair signalling and angiogenic support alongside GHK-Cu's collagen-remodelling activity.

See the full BPC-157 research guide →

GHK-Cu is a naturally occurring copper-binding tripeptide (Glycine-Histidine-Lysine complexed with copper) found in human plasma, urine, and saliva. It has been studied extensively for its role in wound healing, collagen synthesis stimulation, anti-inflammatory activity, and antioxidant effects.

GHK-Cu forms the largest component of GLOW 70 at 50mg per vial. This weighting reflects its established role in connective tissue and skin remodelling research, mechanistic areas not directly covered by BPC-157 or TB-500 alone. Research has also examined GHK-Cu's effects on gene expression, with studies indicating modulation of genes involved in tissue repair and inflammation pathways.

See the full GHK-Cu research guide →

TB-500 is a synthetic analogue of the active region of Thymosin Beta-4, a 43-amino acid protein involved in actin regulation, cell migration, and wound healing. TB-500 promotes cell migration to injury sites, stimulates angiogenesis, and has been studied for anti-inflammatory effects in cardiac and musculoskeletal models.

In the GLOW 70 context, TB-500 complements BPC-157 with systemic cell migration signalling. Where BPC-157 tends toward localised repair effects, TB-500's actin-binding and migration-promoting activity supports broader tissue recruitment. The BPC-157 and TB-500 pairing is well-established in peptide research literature as a complementary stack.

See the full TB-500 research guide → and the BPC-157 + TB-500 stack research guide →

Each compound in GLOW 70 acts through a distinct mechanism, making them non-redundant in combination:

• BPC-157, angiogenesis and localised tissue repair via VEGF and nitric oxide pathways
• GHK-Cu, collagen synthesis, extracellular matrix remodelling, and broad gene-expression modulation
• TB-500, actin regulation, cell migration to injury sites, and systemic anti-inflammatory signalling

Researchers interested in multi-pathway regeneration protocols often combine these compounds precisely because their mechanisms are complementary rather than overlapping. GLOW 70 provides all three in a single vial, simplifying preparation for studies investigating this combination.

The BPC-157 and TB-500 pairing within this blend is sometimes referred to as the "Wolverine stack" in research communities, reflecting the breadth of regenerative pathways the two compounds engage together.

Researchers who additionally want to include a melanocortin-pathway anti-inflammatory compound may wish to consider the KLOW blend, which adds KPV to this same core formulation. KPV (a Lys-Pro-Val tripeptide derived from α-MSH) inhibits NF-κB nuclear translocation and has been studied most extensively in colitis models for reducing colonic inflammation.

GLOW 70 is supplied as a lyophilised powder in a sterile sealed vial. The 70mg total contains GHK-Cu 50mg, BPC-157 10mg, and TB-500 10mg. Reconstitute and store following the standard protocol, see our peptide reconstitution & storage guide (TB-500's longer peptide chain may require slightly more time to dissolve than the other components).

Compound-specific concentrations:

• With 2mL BAC water (recommended): GHK-Cu 25mg/mL · BPC-157 5mg/mL · TB-500 5mg/mL · total 35mg/mL
• With 2.5mL BAC water: GHK-Cu 20mg/mL · BPC-157 4mg/mL · TB-500 4mg/mL · total 28mg/mL

Store reconstituted vial at 2–8°C. Use within 28–30 days. Use the reconstitution calculator to determine draw volumes based on per-compound target concentrations.

GLOW 70 is available from OzPeps as a 70mg lyophilised vial with fast Australia-wide shipping, discreet packaging, and crypto payment accepted. View GLOW 70 stock and pricing →

Individual compounds are also stocked separately for researchers who need to adjust ratios independently, see the BPC-157, GHK-Cu, and TB-500 research guides, or browse the full OzPeps catalogue.

All GLOW 70 products from OzPeps are supplied strictly for in-vitro laboratory and research purposes. Not TGA-approved. Not for human or animal consumption. Researchers are responsible for all applicable regulatory compliance.